Responsible Steps Program prior authorization

Drugs listed in Florida Blue’s Responsible Steps Program (including many antidepressants, antipsychotics, and gabapentin ER products) require prior authorization under the program; prescribers must submit an authorization request using the program-specific forms referenced on the payer’s Authorization Forms page.

• Target drugs include numerous antidepressants, antipsychotics, and gabapentin ER (examples: Cymbalta, Abilify, Lybalvi, Gralise/Horizant).

Prior authorization requires prerequisite trials

Prior authorization requests must include evidence that prerequisite medication trials have been met per the Responsible Steps Program; target drug coverage is conditioned on these prerequisite trials.

• Prerequisite trial expectations vary by therapeutic category and indication (see indication‑specific lists).

Link to Authorization Forms for Responsible Steps Program

Authorization forms for the Responsible Steps Program are available on the payer’s Authorization Forms page; providers must search for and select the document matching the therapeutic category of the requested drug (example: select 'Antidepressants' for Cymbalta).

• Use the Authorization Forms link and choose the therapeutic‑category document when completing a prior authorization.

Prior use required for authorization

Authorization requires documentation of prior use of the specific generic agents appropriate to the indication (behavioral health or indication‑specific pain lists) as listed in the program criteria.

• For antidepressant/behavioral health indications, list of generics includes bupropion, citalopram, desvenlafaxine ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine (including ER), or vilazodone.
• For pain indications, see the neuropathic pain, fibromyalgia, or chronic musculoskeletal pain prerequisite lists.

Generic prior-use requirement

Many target drugs require documented prior use of two or more generic versions of agents in the relevant therapeutic class before approval; exceptions to the two‑generic requirement are specified in the policy.

• Typical requirement: previous trials of two or more generics for many antidepressant and antipsychotic targets.

Prior authorization required for target drugs

Certain branded products listed as program 'target drugs' will not be authorized without prior authorization and demonstration of the prerequisite generic trials specified for that product and indication.

• Examples of target drugs are listed throughout the program document (e.g., Abilify, Seroquel, Cymbalta, Gralise/Horizant).

Prior authorization requirement

Prior authorization approvals are contingent upon documentation showing prior use of the specified generic alternatives appropriate to the indication; this includes behavioral‑health generics or indication‑specific pain agents as listed.

• If the indication is neuropathic pain, previous use of amitriptyline, desipramine, duloxetine, gabapentin, imipramine, or nortriptyline must be documented.
• If fibromyalgia or chronic musculoskeletal pain is the indication, the respective prerequisite lists apply.

Prior use of generics required

Providers must document prior use of the specified generic agents (see the program lists) for the relevant indication (depression/antidepressant, neuropathic pain, fibromyalgia, or chronic musculoskeletal pain) when submitting authorization requests.

• Clinical documentation should reflect prior trials of the listed generics appropriate to the diagnosis being treated.

Antipsychotic generic-trial requirement

For many antipsychotic target drugs, prior authorization requires documented prior use of two or more generic versions of listed antipsychotics; Lybalvi is explicitly noted as an exception that requires only one prior generic trial.

• Antipsychotic generics listed include aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.

Prior authorization requires documented prior drug trials

Prior authorization must include documentation of prior drug trials demonstrating use of the listed generic agents before coverage will be granted for target drugs included in the Responsible Steps Program.

• Refer to the program’s authorization form for the therapeutic category to indicate which prior‑use evidence is provided.

Program prior authorization

Prescribers must submit authorization requests that demonstrate the prerequisite generic trials per the program criteria for the requested target drug and indication.

• Use the program authorization form for the drug’s therapeutic category and include prior‑use history.

Prior authorization required for program drugs

Drugs included in the Responsible Steps Program require prior authorization using the program‑specific authorization forms; providers must demonstrate prerequisite generic trials as specified by indication.

• Examples of included products and the need for prior‑use documentation are listed in the program document.

Prior authorization required

Prior authorization approval depends on evidence of prior use of the listed generic agents appropriate to the specific indication; Lybalvi is an exception requiring only one prior generic trial.

• Documentation must indicate which prerequisite list applies based on the diagnosis (antidepressant, neuropathic pain, fibromyalgia, or chronic musculoskeletal pain).

Prerequisite prior medication use

Submit documentation showing prior use of the specific generic agents listed for the relevant indication (behavioral‑health antidepressants/antipsychotics or indication‑specific analgesics) when requesting authorization.

• Include prior‑use history demonstrating trials of the listed generics; the number of distinct generics required varies by target drug (commonly two; Lybalvi exception noted).

Prerequisite generic trials required

Prior authorization requires documented previous use of the specified generic agents from the program’s prerequisite lists before the target branded agents will be covered.

• For gabapentin ER products, prior use of immediate‑release gabapentin is noted as a prerequisite in the program.

Prior authorization prerequisite: prior-use trials

Prior authorization requests must document previous use of the specified generic alternatives appropriate to the indication; for gabapentin ER formulations this includes prior use of immediate‑release gabapentin.

• Search and use the authorization form for the therapeutic category when submitting evidence.

Prior use of generics required

Prior authorization requires documentation showing prior use of two or more generic versions of listed antidepressants (or other specified prior drugs depending on indication); providers must reference the program lists when submitting requests.

• Indication‑specific alternative prior agents apply for neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.

Prerequisite drug trials

Step‑therapy logic: many target drugs require prior use of two or more generic alternatives from the same therapeutic class; Lybalvi is an explicit exception requiring only one prior generic trial.

• The program defines step requirements by indication and drug class—follow the listed generic‑trial counts.

Step therapy/prerequisite trial requirements

Step therapy for Responsible Steps Program drugs requires prior trials of the specified generics depending on indication; many target drugs require two or more generic trials while some indication branches accept one appropriate alternative agent.

• Indication‑specific lists include neuropathic pain, fibromyalgia, and chronic musculoskeletal pain alternatives.

Step therapy/prerequisite trials

Step‑therapy requirement: previous use of two or more generic versions of listed antipsychotics or antidepressants is generally required for authorization; Lybalvi requires only one prior generic trial.

• Document prior trials of the required number of distinct generics per the program lists.

Step therapy by indication

Step therapy requires prior trials of the specified generic agents by indication: antidepressant list for behavioral‑health indications; neuropathic pain list (amitriptyline, desipramine, duloxetine, gabapentin, imipramine, nortriptyline); fibromyalgia list (amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, tramadol); chronic musculoskeletal pain list (acetaminophen, amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, NSAID, or tramadol).

• Use the branch that corresponds to the member’s diagnosis when documenting prior trials.

Generic-step prerequisite

Many target drugs require prior trial and failure of two or more generic alternatives from the same therapeutic class before approval; Lybalvi requires only one generic prior trial.

• Ensure documentation specifies the distinct generic products tried and dates/duration of therapy as evidence.

Step/prerequisite therapy

Step therapy functions as a prerequisite—providers must show prior use of two or more generics from the specified therapeutic lists (exceptions noted for some drugs/indications).

• Lybalvi is identified as requiring only one prior generic trial.

Indication-specific prerequisite trials

Step therapy requires prior trials of specified generics depending on indication; for neuropathic pain the required prior agents include amitriptyline, desipramine, duloxetine, gabapentin, imipramine, or nortriptyline.

• Document which neuropathic‑pain agent was used previously when submitting authorization.

Antipsychotic step requirement

For many antipsychotic target drugs, prior authorization requires documented use of two or more generic antipsychotics from the listed agents; Lybalvi is an exception requiring only one prior generic trial.

• Listed antipsychotic generics include aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone.

Generic step therapy requirement

Step therapy generally requires prior use of two or more generic versions of listed antidepressants or antipsychotics before a target drug is authorized; Lybalvi is consistently noted as requiring only one generic prior trial.

• Follow the program lists and indicate any exceptions (e.g., Lybalvi) on the authorization form.

Generic trial/step requirements

Step‑therapy requirements include prior use of two or more generic antidepressants (examples listed) OR indication‑specific alternatives for neuropathic pain, fibromyalgia, or chronic musculoskeletal pain; many antipsychotics require two generics (Lybalvi exception).

• Examples of antidepressant generics: bupropion, citalopram, desvenlafaxine ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, venlafaxine (including ER), vilazodone.

Step therapy / prerequisite drugs

Step therapy requires prior use of the specified generic alternatives before coverage of target drugs; typical requirement is previous use of two or more generics, with indication‑specific alternative lists provided.

• Providers should document trials and outcomes (e.g., treatment failure or intolerance) per usual authorization documentation practices.

Step/sequence requirements

Step requirements for many antipsychotics and antidepressants require prior use of two or more generic versions of listed agents; Lybalvi is an explicit exception requiring only one prior generic trial.

• When requesting Lybalvi, include documentation of a single prior generic antipsychotic trial as specified.

Step requirements for antipsychotics/antidepressants

For many antipsychotics and antidepressants, prior authorization will require documentation of two or more prior generic trials from the listed agents; indicate Lybalvi’s single‑generic exception when applicable.

• Ensure prior trials are distinct generic products as required by the policy language.

Step therapy/Prerequisite drugs

Step therapy requires prior trials of two or more generic versions of listed antidepressants or antipsychotics before coverage of target drugs; exceptions (such as Lybalvi requiring only one generic trial) are noted in the policy.

• Document prior trials clearly on the authorization form, including dates and reason for discontinuation if applicable.

Step therapy prior trials

Step‑therapy logic: providers must demonstrate prior trials of two or more generic alternatives (specific lists provided) before target drugs are authorized; Lybalvi requires only one prior generic trial.

• Submit prior‑use history with the authorization to show the required number of distinct generic trials.

Documentation of prior trials

Providers must document prior use(s) of the specified generic medications appropriate to the indication (behavioral health or indication‑specific pain lists) when submitting an authorization request.

• Documentation should reflect which agents were tried, dates of therapy, and reason for discontinuation or failure.

Required prior-medication documentation

Authorization documentation must show previous use of the specified generic medications or alternative agents depending on the indication (examples: two or more generic antidepressants for behavioral‑health targets; specified tricyclics/SNRI/gabapentin for neuropathic pain).

• Include the specific agent names and treatment dates to meet the program’s prerequisite documentation requirements.

Required prior-use documentation

Clinical documentation must show prior use of the specific generic medications listed for the relevant indication (behavioral health antidepressants/antipsychotics or the appropriate pain agents) to meet the program prerequisites.

• When the indication is neuropathic pain, documentation must indicate prior use of agents such as amitriptyline, desipramine, duloxetine, gabapentin, imipramine, or nortriptyline.

Authorization forms

The Authorization Forms page contains the program forms for all Responsible Steps Program drugs; providers must search for and use the form that matches the therapeutic category of the drug being requested.

• Example: select the 'Antidepressants' authorization document for requests involving Cymbalta or other antidepressant targets.

Required prior-use documentation

Documentation must show prior use of specified generic agents appropriate to the drug class and indication (see the indication‑specific prerequisite lists for neuropathic pain, fibromyalgia, and chronic musculoskeletal pain).

• For fibromyalgia, acceptable prior agents include amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, or tramadol.

Required prior-use documentation

Documentation must demonstrate prior use of the specific generic drugs listed for the relevant indication (antidepressants list OR the indicated pain agent lists) before the target drug will be authorized.

• Include dates, trial duration, and reason for discontinuation or inadequate response where relevant.

Authorization form location

Providers should reference the Authorization Forms page and select the document matching the therapeutic category when submitting authorization requests; include the required prior‑use evidence from the program lists.

• Attach prior‑use history and any supporting clinical notes to the authorization form.

Required prior-use documentation

Clinical documentation must show prior use of specified generic agents appropriate to the indication (antidepressant lists or the neuropathic pain/fibromyalgia/chronic musculoskeletal pain lists) before a target drug is authorized.

• Documentation must indicate which prerequisite list applies and which agents were tried.

Required prior trials

Documentation should show prior trials of the specified generic medications appropriate to the indication; the number and identity of required generics vary by drug and indication (typically two distinct generics for many targets; Lybalvi exception noted).

• Where two generics are required, they should be distinct generic products from the program list.

Required prior-use documentation

Providers must document prior use of specified generic medications or indication‑specific alternative agents when submitting an authorization request; this documented prior use serves as the step‑therapy evidence.

• Prior‑use documentation may include pharmacy records, prior authorization notes, or clinical progress notes showing trials and outcomes.

Required documentation of prior medication trials

Documentation must show prior use of specified generic medications tailored to the indication: prior antidepressant trials for depressive indications, or the listed neuropathic pain/fibromyalgia/chronic musculoskeletal pain agents when those are the treated conditions.

• For chronic musculoskeletal pain, acceptable prior agents include acetaminophen, NSAID (oral or topical), amitriptyline, cyclobenzaprine, duloxetine, gabapentin, imipramine, nortriptyline, or tramadol.

Required prior medication documentation

Documentation of prior trials of the specified generic medications (listed by class/condition) is required to meet the Responsible Steps Program prerequisite criteria; include agent names and dates of use.

• If prior trials are not documented, the authorization may be denied.

Required prior-use evidence

Submit prior‑use history showing trials of the specified generic medications; the number of distinct generics required depends on the target drug (commonly two generics; Lybalvi requires only one).

• Include sufficient clinical detail to demonstrate that prior agents were used and failed or were not tolerated when appropriate.

Authorization forms

Providers should reference and use the Authorization Forms page for the specific therapeutic‑category document when submitting authorization requests and include the required prior‑use documentation per the program lists.

• Selecting the correct therapeutic category form (e.g., Antidepressants) ensures the request maps to the applicable prerequisite lists.

Prior use requirement

Failure to document prior use of the required generic agents (per the program’s prerequisite lists) may result in denial of the authorization request.

• Denial risk applies when required number or type of prior generic trials is not shown.

Missing prerequisite trials

If prerequisite trials are missing from the submission (for example, absence of documentation showing two or more prior generic trials where required), the authorization may be denied.

• Ensure all applicable prior trials from the program lists are documented to reduce denial risk.

Prerequisite generic therapy documentation

Failure to document previous use of required generic agents (including indication‑specific alternatives for neuropathic pain, fibromyalgia, or chronic musculoskeletal pain) may trigger denial of authorization.

• Include documentation that clearly indicates which agents were used and the dates/duration.

Prior use prerequisite

Failure to document prior use of required generic agents for the indicated therapeutic category (e.g., antidepressants or neuropathic pain agents) may lead to denial of the authorization request.

• Lybalvi’s single‑generic exception must still be documented when claimed.

Missing prerequisite trials

Failure to document required prior trials (two or more generics where applicable, or the condition‑specific alternatives) may result in non‑authorization of the requested target drug.

• Providers should include prior‑use evidence (pharmacy fills, prior authorizations, clinical notes) to demonstrate trials occurred.

Prior-use prerequisites

Failure to document prior use of required generic drugs (two or more where specified) from the program lists may trigger denial of authorization.

• Denials commonly occur when the submitted record lacks clear evidence of prior trials from the enumerated lists.

Prior-use requirement

Lack of documented prior use of required generic agents for the indicated condition may result in denial; ensure the authorization includes prior‑use history aligned to the applicable prerequisite list.

• Document prior trials for antidepressant, neuropathic pain, fibromyalgia, or chronic musculoskeletal pain indications as applicable.

Prior-use documentation required

If the listed generic alternatives for the indication are not documented as previously used (e.g., two or more generics for antidepressants/antipsychotics or the appropriate pain agents), the authorization is at risk of denial.

• Providers should explicitly reference which prerequisite branch (antidepressant vs pain indication) is met in the submission.

Antipsychotic prior trials

Failure to document previous use of two or more generic versions of listed antipsychotics (unless claiming the Lybalvi exception) may result in non‑approval of the authorization.

• When Lybalvi is requested, include documentation of one prior generic antipsychotic trial as specified.

Prior-use documentation required

Failure to document prior use of required generic agents per the prerequisite lists may trigger denial of authorization for Responsible Steps Program drugs.

• Confirm submission includes adequate prior‑use evidence to meet the stated two‑generic (or exception) requirements.

Missing prerequisite trials

Failure to document prior use of the required generic alternatives (for example, two or more generics for listed antidepressants/SNRIs or the specific agents for neuropathic pain, fibromyalgia, or chronic musculoskeletal pain) may lead to denial.

• Provide objective evidence of prior trials (e.g., fill history, clinic notes) to substantiate the request.

Prerequisite generics not met

Lack of documented prior use of required generic drugs (commonly two or more generics) may trigger denial of the authorization request for target program drugs.

• Providers should ensure prior‑use documentation is complete and clearly matches the program lists.

Missing prerequisite medication trials

Failure to document previous use of required generic therapies for the indicated condition (antidepressants, neuropathic pain agents, fibromyalgia agents, or chronic musculoskeletal pain agents) may trigger denial of authorization.

• Include agent names, dosing, dates, and clinical rationale for discontinuation or failure.

Missing prerequisite trials

Failure to document prior use of required generic agents (two or more where specified, or condition‑specific alternatives) may result in denial of coverage for the requested target drug.

• If prior trials cannot be documented, provide clinical justification and supporting records explaining why the prerequisites cannot be met.

Prior-use documentation required

Failure to document previous use of required generic agents from the program lists may trigger denial of authorization; ensure prior‑use evidence is attached to the authorization form.

• Attach pharmacy fill history or clinical notes showing prior trials and outcomes.

Prior-use requirement

Failure to document prior use of two or more generic agents in the listed classes (or the specific alternative prior agents for neuropathic pain, fibromyalgia, or chronic musculoskeletal pain) may result in denial of the authorization request.

• Documenting the required number of distinct generic trials reduces the risk of denial.